These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 35500942)

  • 1. Are We Ready for a New Approach to Comparing Coverage and Reimbursement Policies for Medical Nutrition in Key Markets: An ISPOR Special Interest Group Report.
    Perugini M; Johnson TJ; Beume TM; Dong OM; Guerino J; Hu H; Kerr K; Kindilien S; Nuijten M; Ofili TU; Taylor M; Wong A; Freijer K
    Value Health; 2022 May; 25(5):677-684. PubMed ID: 35500942
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Payer Perspectives on Patient-Reported Outcomes in Health Care Decision Making: Oncology Examples.
    Brogan AP; DeMuro C; Barrett AM; D'Alessio D; Bal V; Hogue SL
    J Manag Care Spec Pharm; 2017 Feb; 23(2):125-134. PubMed ID: 28125369
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Health technology assessment for cancer medicines across the G7 countries and Oceania: an international, cross-sectional study.
    Jenei K; Raymakers AJN; Bayle A; Berger-Thürmel K; Cherla A; Honda K; Jackson CCGA; Karikios D; Trapani D; Berry S; Gyawali B
    Lancet Oncol; 2023 Jun; 24(6):624-635. PubMed ID: 37269843
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Medical Nutrition Terminology and Regulations in the United States and Europe-A Scoping Review: Report of the ISPOR Nutrition Economics Special Interest Group.
    Freijer K; Volger S; Pitter JG; Molsen-David E; Cooblall C; Evers S; Hiligsmann M; Danel A; Lenoir-Wijnkoop I;
    Value Health; 2019 Jan; 22(1):1-12. PubMed ID: 30661624
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparing access to orphan medicinal products in Europe.
    Zamora B; Maignen F; O'Neill P; Mestre-Ferrandiz J; Garau M
    Orphanet J Rare Dis; 2019 May; 14(1):95. PubMed ID: 31053154
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The ISPOR Good Practices for Quality Improvement of Cost-Effectiveness Research Task Force Report.
    McGhan WF; Al M; Doshi JA; Kamae I; Marx SE; Rindress D
    Value Health; 2009; 12(8):1086-99. PubMed ID: 19744291
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Policies for Use of Real-World Data in Health Technology Assessment (HTA): A Comparative Study of Six HTA Agencies.
    Makady A; Ham RT; de Boer A; Hillege H; Klungel O; Goettsch W;
    Value Health; 2017 Apr; 20(4):520-532. PubMed ID: 28407993
    [TBL] [Abstract][Full Text] [Related]  

  • 8. International comparison of comparative effectiveness research in five jurisdictions: insights for the US.
    Levy AR; Mitton C; Johnston KM; Harrigan B; Briggs AH
    Pharmacoeconomics; 2010; 28(10):813-30. PubMed ID: 20831289
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Shedding Light on Reimbursement Policies of Companion Diagnostics in European Countries.
    Govaerts L; Simoens S; Van Dyck W; Huys I
    Value Health; 2020 May; 23(5):606-615. PubMed ID: 32389226
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development and implementation of health technology assessment in Argentina: two steps forward and one step back.
    Rubinstein A; Pichon-Riviere A; Augustovski F
    Int J Technol Assess Health Care; 2009 Jul; 25 Suppl 1():260-9. PubMed ID: 19527545
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HTA decision-making for drugs for rare diseases: comparison of processes across countries.
    Stafinski T; Glennie J; Young A; Menon D
    Orphanet J Rare Dis; 2022 Jul; 17(1):258. PubMed ID: 35804398
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Establishing a national HTA program for medical devices in Italy: Overhauling a fragmented system to ensure value and equal access to new medical technologies.
    Tarricone R; Amatucci F; Armeni P; Banks H; Borsoi L; Callea G; Ciani O; Costa F; Federici C; Torbica A; Marletta M
    Health Policy; 2021 May; 125(5):602-608. PubMed ID: 33820679
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparing Use of Health Technology Assessment in Pharmaceutical Policy among Earlier and More Recent Adopters in the European Union.
    Beletsi A; Koutrafouri V; Karampli E; Pavi E
    Value Health Reg Issues; 2018 Sep; 16():81-91. PubMed ID: 30316029
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reimbursement policies in the Asia-Pacific for chronic hepatitis B.
    Lim SG; Amarapurkar DN; Chan HL; Crawford DH; Gane EJ; Han KH; Ahn SH; Jafri W; Jia J; Kao JH; Lesmana LA; Lesmana CR; Mohamed R; Phiet PH; Piratvisuth T; Sarin SK; Sollarno JD; Eguchi Y; Mahtab MA; Lee KH
    Hepatol Int; 2015 Jan; 9(1):43-51. PubMed ID: 25788378
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Health Economics Approach to US Value Assessment Frameworks-Summary and Recommendations of the ISPOR Special Task Force Report [7].
    Garrison LP; Neumann PJ; Willke RJ; Basu A; Danzon PM; Doshi JA; Drummond MF; Lakdawalla DN; Pauly MV; Phelps CE; Ramsey SD; Towse A; Weinstein MC
    Value Health; 2018 Feb; 21(2):161-165. PubMed ID: 29477394
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Health Technology Assessment for Molecular Diagnostics: Practices, Challenges, and Recommendations from the Medical Devices and Diagnostics Special Interest Group.
    Garfield S; Polisena J; S Spinner D; Postulka A; Y Lu C; Tiwana SK; Faulkner E; Poulios N; Zah V; Longacre M
    Value Health; 2016; 19(5):577-87. PubMed ID: 27565275
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An International Review of Health Technology Assessment Approaches to Prescription Drugs and Their Ethical Principles.
    Rand LZ; Kesselheim AS
    J Law Med Ethics; 2020 Sep; 48(3):583-594. PubMed ID: 33021189
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Implementation Road Map of Health Technology Assessment in Middle-Income Countries: The Case of Jordan.
    Almomani E; Alabbadi I; Fasseeh A; Al-Qutob R; Al-Sharu E; Hayek N; Tarawneh MR; Kaló Z
    Value Health Reg Issues; 2021 Sep; 25():126-134. PubMed ID: 34015521
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of health technology assessment on pharmaceutical reimbursement in selected middle-income countries.
    Oortwijn W; Mathijssen J; Banta D
    Health Policy; 2010 May; 95(2-3):174-84. PubMed ID: 20074829
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Health Economics in the Field of Prosthetics and Orthotics: A Global Perspective.
    Kannenberg A; Seidinger S
    Can Prosthet Orthot J; 2021; 4(2):35298. PubMed ID: 37615010
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.